Dianthus Therapeutics, Inc. (DNTH)

Market Cap	3.46B +455.8%
Revenue (ttm)	2.04M -67.3%
Net Income	-162.34M
EPS	-4.20
Shares Out	44.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,300,962
Open	80.45
Previous Close	80.32
Day's Range	76.22 - 82.27
52-Week Range	13.37 - 88.02
Beta	1.24
Analysts	Strong Buy
Price Target	121.90 (+56.56%)
Earnings Date	Mar 9, 2026

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: DNTH
• Website: https://dianthustx.com

Financial Performance

In 2025, Dianthus Therapeutics's revenue was $2.04 million, a decrease of -67.35% compared to the previous year's $6.24 million. Losses were -$162.34 million, 91.1% more than in 2024.

Analyst Summary

According to 11 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $121.9, which is an increase of 56.56% from the latest price.

Price Target

$121.9

(56.56% upside)

Analyst Consensus: Strong Buy